$CTIC News Insider filings one way to track tricky

New Post Public Reply Private Reply Replies (0) Message Board

Jan 28, 2014 at 11:02 AM

$CTIC News

Insider filings one way to track tricky micro-cap biotechs 11:14 a.m. Oct. 24, 2012 - blogs.marketwatch.com
Friday’s biggest gaining and declining stocks 3:27 p.m. Oct. 5, 2012 - Greg Morcroft
Cell Therapeutics down 21% in premarket 6:15 a.m. Oct. 5, 2012 - Steve Gelsi
Tuesday’s biggest gaining and declining stocks 3:53 p.m. Oct. 2, 2012 - MarketWatch
Cell Therapeutics up 21% in premarket 7:38 a.m. Oct. 2, 2012 - Steve Gelsi
CTIC gets orphan drug status for brain cancer drug 6:37 a.m. Oct. 2, 2012 - MarketWatch.com
Cell Therapeutics: progress with lymphoma Drug 5:59 a.m. Sept. 24, 2012 - MarketWatch.com
Tuesday’s top gaining and declining stocks 3:57 p.m. Sept. 11, 2012 - MarketWatch
Cell Therapeutics soars 24% on EU drug launch 9:12 a.m. Sept. 11, 2012 - Val Brickates Kennedy
Tuesday’s biggest gaining and declining stocks 4:01 p.m. Sept. 4, 2012 - Greg Morcroft
Updates, advisories and surprises 4:01 p.m. July 31, 2012 - MarketWatch
Cell Therapeutics announces stock placement 10:45 a.m. July 31, 2012 - Val Brickates Kennedy
Friday’s biggest gaining and declining stocks 4:21 p.m. Feb. 17, 2012 - Kate Gibson
Monday’s biggest gaining and declining stocks 4:49 p.m. Jan. 30, 2012 - Kate Gibson
Cell Therapeutics pulls application; shares slump 1:25 p.m. Jan. 30, 2012 - MarketWatch.com
Stocks to watch Monday: Blue Coat, Cooper 4:35 p.m. Dec. 9, 2011 - William Spain
Friday’s biggest gaining & declining stocks 4:35 p.m. Dec. 9, 2011 - Kate Gibson
Thursday’s biggest gaining & declining stocks 3:59 p.m. June 30, 2011 - Kate Gibson
Cell Therapeutics tumbles over offerings 8:09 a.m. June 30, 2011 - MarketWatch.com

Is The Healthcare Sector Pulling Back Or Crashing? 5:40 a.m. Today - Seeking Alpha
First Week Of CTIC January 2016 Options Trading 1:18 p.m. Jan. 22, 2014 - TheStreet.com
Cell Therapeutics (CTIC) Highlighted As Today's Perilous Reversal Stock 9:46 a.m. Jan. 22, 2014 - TheStreet.com
It's Hard to Believe, but Biotech Stocks Are Starting 2014 Hotter Than 2013 7:00 a.m. Jan. 21, 2014 - TheStreet.com
Five Worst, Pandering Drug Stocks of J.P. Morgan Healthcare Confab Week 3:52 p.m. Jan. 17, 2014 - TheStreet.com
Cell Therapeutics provides corporate update, share rise 8:25 a.m. Jan. 14, 2014 - Seeking Alpha
Cell Therapeutics Regains Rights to Two In-Development Cancer Medicines 4:47 p.m. Jan. 13, 2014 - Wall St. Cheat Sheet
The J.P. Morgan Healthcare Confab Monday Morning News Dump 9:06 a.m. Jan. 13, 2014 - TheStreet.com
Cell Therapeutics regains rights to cancer compounds from Novartis 8:23 a.m. Jan. 13, 2014 - Seeking Alpha
Cell Therapeutics to Reacquire Rights to Two Anti-Cancer Compounds from Novartis 5:01 a.m. Jan. 13, 2014 - benzinga.com
Time to Analyze Small-Caps Again 1:00 p.m. Jan. 10, 2014 - RealMoney.com
Cell Therapeutics Inc. (CTIC) Shares March Higher, Can It Continue? - Tale of the Tape 7:47 a.m. Jan. 7, 2014 - Zacks.com
BAX Recalls Parenteral Nutrition Injections - Analyst Blog 7:15 p.m. Jan. 6, 2014 - Zacks.com
Is Cell Therapeutics Turning Over A New Leaf In 2014? 11:35 a.m. Jan. 6, 2014 - Seeking Alpha
Cell Therapeutics rallies on NICE nod for Pixuvri 9:02 a.m. Jan. 6, 2014 - Seeking Alpha
FDA lifts partial clinical hold on Cell Therapeutics drug 7:04 a.m. Jan. 2, 2014 - Seeking Alpha
Cell Therapeutics Announces Removal of Partial Clinical Hold on Tosedostat 6:19 a.m. Jan. 2, 2014 - benzinga.com
2 Speculative, But Attractive $2 Biotech Plays 7:19 a.m. Dec. 30, 2013 - Seeking Alpha
BAX Up on FDA Nod and CE Marking - Analyst Blog 5:30 p.m. Dec. 24, 2013 - Zacks.com
Cell Therapeutics Receives Remaining $5 million Under Existing Loan Financing Agreement 4:56 a.m. Dec. 18, 2013 - benzinga.com

Cell Therapeutics Announces GOG Completes Patient Enrollment in GOG-0212 Phase 3 Clinical Trial of Paclitaxel Poliglumex (Opaxio™) as Maintenance Therapy in Ovarian Cancer 1:30 a.m. Today - PR Newswire - PRF
Most Active Stocks Range from Online Game Maker to Biopharmaceuticals: Zynga Inc. (NASDAQ:ZNGA), Dynavax Technologies Corp. (NASDAQ: DVAX), Cell Therapeutics Inc. (NASDAQ:CTIC) 7:22 a.m. Jan. 20, 2014 - ACCESSWIRE
Morning Buzzers: Cell Therapeutics Inc, Stratasys, Galena Biopharma, Cliffs Natural Resources 10:52 a.m. Jan. 14, 2014 - ACCESSWIRE
Cell Therapeutics Announces 2014 Outlook and Recent Drug Portfolio Progress 1:30 a.m. Jan. 14, 2014 - PR Newswire - PRF
Cell Therapeutics Reaches Agreement to Reacquire Rights to Two Anti-Cancer Compounds 1:30 a.m. Jan. 13, 2014 - PR Newswire - PRF
Study Updates, Notices, Quarterly Reports, and Revenue Guidance Updates - Research Report on NPS Pharmaceuticals, Oramed, PAREXEL, PhotoMedex, and Cell Therapeutics 8:00 a.m. Jan. 7, 2014 - PR Newswire
PIXUVRI® (pixantrone) Receives Positive Final Appraisal Determination from NICE 1:30 a.m. Jan. 6, 2014 - PR Newswire
Biotech Industry Stock Update: Cell Therapeutics, Sarepta Therapeutics, ACADIA Pharma, and Medivation 8:00 a.m. Jan. 2, 2014 - PR Newswire
Cell Therapeutics Announces Removal of the Partial Clinical Hold on Tosedostat 1:30 a.m. Jan. 2, 2014 - PR Newswire
Cell Therapeutics Receives Remaining $5 million Under Existing Loan Financing Agreement 1:30 a.m. Dec. 18, 2013 - PR Newswire
Positive Trend Scan List: Cell Therapeutics Inc, Micron Technology, Tiger Oil and Energy, General Motors, Twitter Inc 9:25 a.m. Dec. 10, 2013 - PR Newswire
Cell Therapeutics Announces Presentation of Interim Results from Phase 2 Tosedostat Trial in Older Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) at ASH Annual Meeting 1:30 a.m. Dec. 10, 2013 - PR Newswire
Integrated Safety and Efficacy Analysis of Phase 2 Clinical Trials of Pacritinib in Patients with Myelofibrosis and Low Platelet Counts Presented at ASH Annual Meeting 11:30 a.m. Dec. 9, 2013 - PR Newswire
Breakfast Technical Briefing: Sarepta Therapeutics, ACADIA Pharma, Cell Therapeutics, and Medivation 11:23 a.m. Dec. 6, 2013 - PR Newswire
Cell Therapeutics and GKV-SV Reach Agreement on Pricing of PIXUVRI® (pixantrone) in Germany 1:30 a.m. Dec. 4, 2013 - PR Newswire
ACHN, CTIC, DRYS and FREE added to NASDAQ Active Stock Watch List at GSR 10:00 a.m. Dec. 2, 2013 - ACCESSWIRE
Bullish Stocks Analysis: Apple Inc, Facebook Inc, Cell Therapeutics Inc, Qihoo 360 Technology 9:32 a.m. Dec. 2, 2013 - ACCESSWIRE
Cell Therapeutics Receives $5 Million Milestone Payment for TRISENOX® 1:30 a.m. Dec. 2, 2013 - PR Newswire
Upcoming Investor Conference Presentations, Donations and Acquisitions - Research Report on Jazz Pharmaceuticals, DENTSPLY, Teleflex, DexCom, and Cell Therapeutics 8:00 a.m. Nov. 28, 2013 - PR Newswire
Financial Results, Agreements, Meetings, and Clinical Trials - Research Report on Cell Therapeutics, Akorn, Ligand, Intercept Pharmaceuticals and Ariad Pharmaceuticals 8:00 a.m. Nov. 20, 2013 - PR Newswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Galleon Forge Two Puts Europe on the AI Map

Dublin Hosts Europe's AI Sovereignty Leap If they ever told you Europe was playing catch-up in the high-tech race, someone missed the boat. Armada and Johnson Controls just put Europe right on the AI map. They're cranking up production at Galleon Forge Two in Dublin. Now we're talking about a sovereign AI infrastructure, not that rent-a-cloud deal that's been dangling...

Gilat's Revenue Dip Spurs Legal Scrutiny for Investors

Gilat Satellite's Surprise Revenue Shortfall If anybody thought the satellite business was all about science fiction-esque technology, here's a reality check: when earnings don't meet expectations, shareholders get jittery. This seems to be exactly what's happening with Gilat Satellite Networks Ltd. (NASDAQ: GILT). After twice reaffirming their fiscal 2026 revenue...

PMET's High-Stakes Call on Shaakichiuwaanaan Update

Inside PMET Resources' Critical Investor Briefing Now, this is the kind of investor chatter that cuts to the core of PMET's game plan. We're talking the big guns coming out with PMET Resources (TSX: PMET) as they gear up for what's poised to be a tell-all investor teleconference about their Shaakichiuwaanaan Project. Yep, mark your calendars because on Tuesday, November...

Brent Crude's Tumult: Oil Giants Weather Market Shifts

Oil Market Faces Uncertain Waves The energy sector's a rough sea these days, with Brent crude prices yo-yoing close to that $100 mark. If you're looking for clarity, don't hold your breath—the EIA's latest report suggests we’re sticking near this price for the foreseeable future before easing into more palatable waters come late 2027. But we ain't there yet, as U.S....

Day Out Snacks Brings Back Sold-Out Peppermint Bark

Spicing Up the Holidays with a Best-Seller Return You've got to love when a brand nails it in the holiday treat department, and Day Out Snacks is playing a winning hand by bringing back their Peppermint Bark protein balls. Here we are again, one year after they flew off the shelves like Santa spotted on Christmas Eve. And let me tell you, this re-release has the potential...

Ares Management Faces Fintech with $691B Assets

Anticipation Builds: Ares Awaits TD Cowen Spotlight Ah, Ares Management, the Wall Street heavyweight clocking a colossal $691 billion in assets. Now, they’re angling to dish out some strategic insights. With the TD Cowen 2026 Financials & Fintech Conference set to roll on November 18, what’s better than watching these investment titans take the stage with their CFO...

Third Lake Parts Ways with WaterView Retail Center

Third Lake Partners Exits WaterView Retail in Florida Alright, you don't stumble across deals like this every day. Third Lake Partners just tossed the keys to their WaterView Retail Center in St. Petersburg, wrapping up the retail and residential parts under one roof with Walton Street Capital. It only took a cool five years since its completion in 2021, but hey, better...

Alyssa Bunch: Big Moves in Tennessee Real Estate

Navigating the Tennessee Real Estate Maze If you're talking about where the real estate action happens in Tennessee, you'd better mention Alyssa Bunch, the Vanderbilt-educated dynamo who turns the unforsale into the must-buy. Most of the deals she orchestrates are invisible to the public eye until they're all but written in ink and ready to reshape landscapes—or, more...

WZC Networking Celebrates Two Decades of Growth

From Humble Beginnings to Industry Authority No one ever started a business thinking it would last two decades without at least a bit of grit and determination. Back in 2006, John Wierzgac decided to leap into the unknown with WZC Networking. It all began with three stalwart customers and a single engineering brain powered by resolve. John's motivation stemmed from...

Southfield Capital Exits TFS to AEA Investors

By Lucas Young Updated Nov 10, 2026 Category News Views 123

A Breakthrough Carve-Out Success Story A story that starts with a carve-out and winds up with a strategic sale reeks of experience, and that's precisely what Southfield Capital did with TFS. Back in 2024, they snagged TFS through a carve-out and didn't just sit on it like a lazy trader watching stock tickers race by. Instead, they pushed the envelope with smart...